Crossmark

Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors

Crossref DOI link: https://doi.org/10.1007/s10637-017-0463-y

Published Online: 2017-04-08

Published Print: 2017-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lee, Su Jin

Lee, Seon Young

Lee, Weon Sup

Yoo, Jin San

Sun, Jong-Mu

Lee, Jeeyun

Park, Se Hoon

Park, Joon Oh

Ahn, Myung-Ju

Lim, Ho Yeong

Kang, Won Ki

Park, Young Suk
Funding

Funding for this research was provided by:

Ministry of Health & Welfare, Republic of Korea (HI14C2750)
License Information

Text and Data Mining valid from 2017-04-08

Version of Record valid from 2017-04-08
More Information

Article History

Received: 19 February 2017

Accepted: 27 March 2017

First Online: 8 April 2017

Compliance with ethical standards

:

: None declared.

: The study was conducted in accordance with the Declaration of Helsinki. The study protocol was approved by the Institutional Review Board at Samsung Medical Center and registered in NCT#01660360.

: Informed consent was obtained from all individual participants included in the study.

Document is current

Any future updates will be listed below